| Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial KJ Chappell, FL Mordant, Z Li, DK Wijesundara, P Ellenberg, ... The Lancet Infectious Diseases 21 (10), 1383-1394, 2021 | 98 | 2021 |
| SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein EA Albornoz, AA Amarilla, N Modhiran, S Parker, XX Li, DK Wijesundara, ... Molecular psychiatry 28 (7), 2878-2893, 2023 | 75 | 2023 |
| Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2 D Watterson, DK Wijesundara, N Modhiran, FL Mordant, Z Li, ... Clinical & translational immunology 10 (4), e1269, 2021 | 53 | 2021 |
| The changing epidemiology worldwide of Mycobacterium ulcerans DP O'Brien, I Jeanne, K Blasdell, M Avumegah, E Athan Epidemiology & infection 147, e19, 2019 | 38 | 2019 |
| Molecular clamp stabilised Spike protein for protection against SARS-CoV-2 D Watterson, D Wijesundara, N Modhiran, F Mordant, Z Li, M Avumegah, ... | 15 | 2020 |
| Rapid response subunit vaccine design in the absence of structural information DK Wijesundara, MS Avumegah, J Lackenby, N Modhiran, A Isaacs, ... Frontiers in immunology 11, 592370, 2020 | 14 | 2020 |
| SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction E Albornoz, AA Amarilla, N Modhiran, S Parker, XX Li, DK Wijesundara, ... bioRxiv, 2022.01. 11.475947, 2022 | 5 | 2022 |
| First report of a phase 1 randomised trial of molecular clamp-stabilised spike protein-based and MF59-adjuvanted vaccine for SARS-CoV-2 KJ Chappell, FL Mordant, Z Li, DK Wijesundara, P Ellenberg, J Lackenby, ... | 3 | 2021 |
| Availability and use of Standards in vaccine development MS Avumegah, G Mattiuzzo, A Särnefält, M Page, K Makar, J Lathey, ... npj Vaccines 8 (1), 95, 2023 | 2 | 2023 |
| Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis MS Avumegah, NT Waidyatillake, WP Michalski, DP O’Brien, TM Nelson, ... PLOS Neglected Tropical Diseases 14 (4), e0008172, 2020 | 2 | 2020 |
| Rapid application of the molecular clamp platform for SARS-CoV-2 D Watterson, DK Wijesundara, N Modhiran, FL Mordant, Z Li, ... | 1 | 2020 |
| Epidemiology of Buruli ulcer cases and a potential screening test for exposure M Avumegah Deakin University, 2018 | 1 | 2018 |
| Descriptive analysis in time and space of recorded data for Buruli Ulcer occurrence in Victoria over 22 years MS Avumegah, EL Tay, S Alexandersen, WP Michalski, DP O’Brien, ... bioRxiv, 413542, 2018 | 1 | 2018 |
| Order Hemiptera: The true host involved in Mycobacterium ulcerans transmission, or is it an innocent by-stander? MS Avumegah, C Wejse PeerJ PrePrints, 2014 | 1 | 2014 |
| Rapid diagnostic test: a critical need for outbreak preparedness and response for high priority pathogens SA Yimer, BB Booij, G Tobert, A Hebbeler, P Oloo, P Brangel, ... BMJ Global Health 9 (4), e014386, 2024 | | 2024 |
| Mycobacterium ulcerans Disease and Host Immune Responses MS Avumegah New Advances in Neglected Tropical Diseases, 2022 | | 2022 |
| SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction (preprint) EA Albornoz, AA Amarilla, N Modhiran, S Parker, XX Li, DK Wijesundara, ... | | 2022 |
| Molecular clamp stabilised Spike protein for protection against SARS-CoV-2 (preprint) D Watterson, D Wijesundara, N Modhiran, F Mordant, Z Li, M Avumegah, ... | | 2020 |
| Rapid Application of the Molecular Clamp Platform for SARS-CoV-2 (preprint) D Watterson, D Wijesundara, N Modhiran, F Mordant, Z Li, M Avumegah, ... | | 2020 |
